-
Something wrong with this record ?
Amyloid cardiomyopathy
L. Karafiatova, T. Pika
Language English Country Czech Republic
Document type Journal Article
Grant support
NV16-31156A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
28145535
DOI
10.5507/bp.2017.001
Knihovny.cz E-resources
- MeSH
- Amyloidosis complications diagnosis physiopathology therapy MeSH
- Early Diagnosis MeSH
- Cardiomyopathies diagnosis etiology physiopathology therapy MeSH
- Humans MeSH
- Prognosis MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Amyloidosis is a heterogeneous group of diseases characterized by the deposition of amyloid. It is caused by extracellular deposition of insoluble fibrils with beta-pleated sheet configuration. The protein misfolding abnormalities result in amyloid fibrils and may manifest as primary, secondary, or familial amyloidosis. Amyloid deposition can occur in multiple organs (eg, heart, liver, kidney, skin, eyes, lungs, nervous system) resulting in a variety of clinical manifestations. Cardiac involvement can occur as part of a systemic disease or as a localized phenomenon. Cardiac involvement in all types of amyloidosis represents a major negative prognostic factor. Early diagnosis, multi-disciplinary cooperation and proper therapy are key aspects of care for patients with amyloid cardiomyopathy. Early diagnosis is crucial, especially in AL amyloidosis, as patients with advanced heart disease are unsuitable candidates for modern, effective hematological treatment including autologous stem cell transplantation. Despite signal development in diagnostics and therapy, the prognosis for patients with advanced cardiac involvement remains poor. This article is an overview of amyloidosis, providing information about the characteristics of cardiac amyloidosis, and present a structured approach to diagnosis, treatment and prognosis of this condition.
Department of Hemato Oncology University Hospital Olomouc Czech Republic
Department of Internal Medicine 1 Cardiology University Hospital Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016118
- 003
- CZ-PrNML
- 005
- 20180524072419.0
- 007
- ta
- 008
- 180514s2017 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2017.001 $2 doi
- 035 __
- $a (PubMed)28145535
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Karafiátová, Lucie $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0224576
- 245 10
- $a Amyloid cardiomyopathy / $c L. Karafiatova, T. Pika
- 520 9_
- $a Amyloidosis is a heterogeneous group of diseases characterized by the deposition of amyloid. It is caused by extracellular deposition of insoluble fibrils with beta-pleated sheet configuration. The protein misfolding abnormalities result in amyloid fibrils and may manifest as primary, secondary, or familial amyloidosis. Amyloid deposition can occur in multiple organs (eg, heart, liver, kidney, skin, eyes, lungs, nervous system) resulting in a variety of clinical manifestations. Cardiac involvement can occur as part of a systemic disease or as a localized phenomenon. Cardiac involvement in all types of amyloidosis represents a major negative prognostic factor. Early diagnosis, multi-disciplinary cooperation and proper therapy are key aspects of care for patients with amyloid cardiomyopathy. Early diagnosis is crucial, especially in AL amyloidosis, as patients with advanced heart disease are unsuitable candidates for modern, effective hematological treatment including autologous stem cell transplantation. Despite signal development in diagnostics and therapy, the prognosis for patients with advanced cardiac involvement remains poor. This article is an overview of amyloidosis, providing information about the characteristics of cardiac amyloidosis, and present a structured approach to diagnosis, treatment and prognosis of this condition.
- 650 _2
- $a amyloidóza $x komplikace $x diagnóza $x patofyziologie $x terapie $7 D000686
- 650 _2
- $a kardiomyopatie $x diagnóza $x etiologie $x patofyziologie $x terapie $7 D009202
- 650 _2
- $a časná diagnóza $7 D042241
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pika, Tomáš $u Department of Hemato-Oncology, University Hospital Olomouc, Czech Republic $7 xx0071238
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 161, č. 2 (2017), s. 117-127
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28145535 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20180514 $b ABA008
- 991 __
- $a 20180524072604 $b ABA008
- 999 __
- $a ok $b bmc $g 1303314 $s 1012958
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 161 $c 2 $d 117-127 $e 20170201 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- GRA __
- $a NV16-31156A $p MZ0
- LZP __
- $b NLK118 $a Pubmed-20180514